Concepedia

Anna Vanazzi

AV

Statistics

Publications

22

Citations

604

H-Index

16

Active since

2003

Affiliations

European Institute of Oncology(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Institute of Oncology Research

Azienda Ospedaliera Citta' della Salute e della Scienza di Torino

Fondazione IRCCS Istituto Nazionale dei Tumori

Anna Vanazzi is an author at European Institute of Oncology specializing in medicine, pathology, and oncology.

ORCID

Top concepts

Publications per year

2003–2024

22

Publications

22

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

Thomas E. Witzig, Kensei Tobinai, Luigi Rigacci et al. · Annals of Oncology · 2017 · 64 citations · Full text

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03

Christian Taverna, Giovanni Martinelli, Felicitas Hitz et al. · Journal of Clinical Oncology · 2015 · 62 citations · Full text

Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

Emanuele Zucca, Stéphanie Rondeau, Anna Vanazzi et al. · Blood · 2019 · 58 citations · Full text

High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment

Marta Cremonesi, Mahila Ferrari, Chiara Maria Grana et al. · Journal of Nuclear Medicine · 2007 · 54 citations · Full text

High activity <sup>90</sup>Y‐ibritumomab tiuxetan (Zevalin<sup>®</sup>) with peripheral blood progenitor cells support in patients with refractory/resistant B‐cell non‐Hodgkin lymphomas

Pier Francesco Ferrucci, Anna Vanazzi, Chiara Maria Grana et al. · British Journal of Haematology · 2007 · 44 citations

1–5 of 22